



HIV/AIDS Prevention Formulation Design and Optimization and Its Pharmacokinetic-Pharmacodynamic Evaluation

Guest Editors:

Dr. José Gerardo García-Lerma

Laboratory Branch, Division of
HIV Prevention, Centers for
Disease Control and Prevention,
1600 Clifton Road, Atlanta, GA
30329, USA

Dr. S. Rahima Benhabbour

Biomedical Engineering,
University of North Carolina,
Chapel Hill, NC 27599, USA

Deadline for manuscript
submissions:

closed (30 May 2024)

Message from the Guest Editors

Dear Colleagues,

Daily oral re-exposure prophylaxis (PrEP) has been highly effective in preventing HIV acquisition when taken as prescribed, although inadequate adherence reduces efficacy and public health benefits. The development of new long-acting PrEP modalities that do not require frequent dosing is being actively pursued in order to overcome suboptimal drug adherence to daily oral PrEP. A bi-monthly injection of cabotegravir formulated as a nanoparticle suspension for intramuscular injection was the first long-acting regimen approved by the Food and Drug Administration (FDA) for PrEP in men and women.

This Special Issue invites original research papers, communications or review articles that focus on the development of new long-acting drug formulations and controlled/extended release technologies for HIV PrEP, including (but not limited to) prodrug modifications, subdermal/subcutaneous implants, subcutaneous/intramuscular injectables, microarray patches, intravaginal rings, vaginal gels, inserts, and films. Articles studying pharmacokinetic/pharmacodynamic relationships in animal models are also considered as highly relevant for this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma